Published on 26 August 2021
Description:
Modifying practices to assess pandemic-era real-world data, cancer care post-COVID, diversity & inclusion, epilepsy and inclusion in society, controlling the MedTech explosion, M&A activity in the life sciences sector, digital catch up and more. Plus interviews with the ABPI’s Ben Osborn and Roche UK’s Thom Renwick.
Categories:
PharmaTimesPreview:
30 articles from this collection:
Cover
2 - PharmaTimes Sales Awards 2021
3 - From the editor
This month PharmaTimes presents Alantra’s annual ranking of the fastest growing pharma companies in the UK, and again there is much cause for celebration. As the analysis shows, a relentless focus on innovation and a determination to solve problems hindering patient outcomes are key traits that have helped those at the top shine in a sector that saw average growth of 33% in 2020. Taking top-spot in the ranking, Exscientia has almost quadrupled its revenue in the last two years, a remarkable achievement and even more so considering the current climate. Turn to page 20 for an in-depth look at the other companies reaching new heights and what’s fuelling their success.
4-5 - Contents
6 - PharmaTimes Marketer of the Year Awards 2021
7 - NHS News
8 - Medicine News
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has launched a public consultation on the potential reclassification of two progestogen-only, oral contraceptive pills containing desogestrel: Lovima 75mcg and Hana 75mcg film-coated tablets.
9 - Hot or Not
ViiV Healthcare’s Rukobia (fostemsavir) has received a marketing authorisation in Europe for the treatment of adults with multidrug-resistant HIV-1 infection. The EU has cleared use of the drug in patients who cannot otherwise receive a suppressive antiviral-regimen. Rukobia – a first-in-class HIV attachment inhibitor – is designed to target the first step of the HIV life-cycle. According to ViiV, it shows no cross-resistance to other currently approved antiretroviral classes, offering a new option for patients who are multidrug-resistant and at a higher risk of disease progression or death.
10 - Covid News
The UK government is streaming funds of £18.5 million into four research projects striving to improve understanding of the longer-term effects of COVID-19, known as long COVID.
11 - LabCorp
12-13 - Healthcare
The UK government has unveiled plans for a new round of NHS reforms that aim to pave the way for health and care services to work more closely together, improve care and tackle health inequalities.
14 - Industry News
15 - Diversity and inclusion - Sarah Scanlon
16-18 - Cancer care in a post-COVID environment
19 - Grifols
20-21 - Are you ready to dive into a new era for medicines funding?
22-23 - Smart People: Ben Osborn
24 - Elitech
26-27 - Digital catch up
28 - 29 - Epilepsy and inclusion in society
The impact of COVID-19 in 2020 has had significant ramifications as healthcare professionals have had to switch focus to managing and controlling the virus, which has left a huge hole for patients with long-term conditions, such as cancer.
30-31 - In the real world
34-35 - Trends, predictions and challenges for M&A activity
36-37 - Martech or mindset?
38-39 - Patient file: Parkinson’s Disease
40-41 - Smart People: Thom Renwick
42-43 - Appointments
44-45 - Rules of engagement
47 - PharmaTimes International Clinical Researcher of the Year 2021
48 - Labcorp
32-33 - Controlling the MedTech explosion
PharmaTimes
PharmaTimes is the UK’s leading pharmaceutical magazine, tracking the trends and issues that affect the industry here in the UK, in Europe and across the world. We deliver independent, authoritative and trustworthy content through impartial, balanced and informed opinion and analysis.